GENFLEET-B (02595) saw its shares rise by 7.34% in morning trading, currently priced at HKD 48.58, with a turnover of HKD 52.61004 million.

On April 23, according to an announcement from GENFLEET-B, the company reported that multiple preclinical research findings for GFH375/VS-7375 were selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Among these, data from two studies were included in the Late-breaking Research Abstracts. The disclosed research systematically explored the potential resistance mechanisms and reversibility of RAS inhibitors, demonstrating GFH375's anti-resistance potential beyond that of KRAS G12D (ON) inhibitors and providing a solid scientific foundation for various combination therapy strategies. The related experiments presented at the annual meeting were led by GENFLEET's partner, Verastem Oncology.

GFH375 entered the world's first Phase III registrational clinical trial for an oral KRAS G12D inhibitor in China in 2025. In 2026, GFH375 became the first KRAS G12D inhibitor to receive two Breakthrough Therapy Designations in China for monotherapy, targeting G12D-mutated pancreatic cancer and non-small cell lung cancer (NSCLC), respectively. Additionally, the product has been granted Fast Track designation by the U.S. FDA for the treatment of G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC) across various lines of therapy. Currently, multiple monotherapy and combination therapy trials for GFH375/VS-7375 are underway both domestically and internationally.